Related Experiment Videos
High risk lymphoblastic leukemia in children: prognostic factors and management
1Department of Hematology-Oncology, St Jude Children's Research Hospital, Memphis.
Insights
Prognostic factors for childhood acute lymphoblastic leukemia (ALL) include high leukocyte count and extreme age at diagnosis. Advances in immunology and genetics identify new risk factors, enabling tailored therapies for better survival rates.
Area of Science:
- Pediatric Oncology
- Hematology
- Clinical Genetics
Background:
- Childhood acute lymphoblastic leukemia (ALL) prognosis is influenced by various clinical and biological features.
- The predictive value of these factors is dynamic and depends on therapeutic efficacy.
Purpose of the Study:
- To review the prognostic significance of clinical and biological features in childhood ALL.
- To highlight the evolving role of immunophenotypes and genetic abnormalities in risk stratification.
- To discuss advancements in therapy tailored to patient risk.
Main Methods:
- Review of established and emerging prognostic indicators in childhood ALL.
- Analysis of how immunophenotypes and karyotypic abnormalities impact outcomes.
- Discussion of current and investigational therapeutic strategies.
Main Results:
- High leukocyte count and extreme age ( <1 or >10 years) are key indicators of poor prognosis.
- Blast cell immunophenotypes and karyotypic abnormalities are now recognized as independent prognostic factors.
- Current aggressive therapies achieve long-term survival in over 60% of patients.
Conclusions:
- Prognostic factor assessment is crucial for tailoring childhood ALL treatment.
- Ongoing research focuses on improving outcomes for high-risk patients.
- Innovative therapies like bone marrow transplantation and phenotype-specific treatments are under investigation.
Abstract:
Most of the presenting clinical and biological features that have prognostic significance in childhood acute lymphoblastic leukemia are closely related, although they are not equally important. The predictive value of these factors can vary with the efficacy of the therapy delivered. Although there are no uniform criteria to define a high-risk group, an initially high leukocyte count and an age less than 1 or greater than 10 years at diagnosis are universally accepted as the most powerful indicators of a poor outcome. With advances in immunology and genetics, blast cell immunophenotypes and karyotypic abnormalities have emerged as independently significant prognostic factors. With this information, therapy can be tailored for patients at various risks of treatment failure. Using early aggressive therapy, more than 60% of patients are expected to be long-term survivors, but better therapy is still needed for those at high risk of relapse. Innovative approaches, such as bone marrow transplantation, phenotype-specific treatment, or pharmacokinetic-directed therapy, are being tested.